Ovid Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ovid Therapeutics's estimated annual revenue is currently $214.1M per year.
- Ovid Therapeutics's estimated revenue per employee is $4,654,130
- Ovid Therapeutics's total funding is $134.1M.
- Ovid Therapeutics's current valuation is $213.1M. (January 2022)
Employee Data
- Ovid Therapeutics has 46 Employees.
- Ovid Therapeutics grew their employee count by 15% last year.
Ovid Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Assistant To CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Regulatory Officer, Head Global Regulatory Affairs | Reveal Email/Phone |
4 | Chief Development Officer | Reveal Email/Phone |
5 | Chief Corporate Affairs Officer | Reveal Email/Phone |
6 | Chief Development Officer (CDO) | Reveal Email/Phone |
7 | SVP, Global Regulatory Affairs, Pharmacovigilance and Biometrics | Reveal Email/Phone |
8 | VP, Global Market Access & Patient Services | Reveal Email/Phone |
9 | Head Epilepsy Research | Reveal Email/Phone |
10 | SVP, Finance and Financial Planning | Reveal Email/Phone |
Ovid Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is Ovid Therapeutics?
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients. Review our community guidelines: http://www.ovidrx.com/community-guidelines/
keywords:N/A
$134.1M
Total Funding
46
Number of Employees
$214.1M
Revenue (est)
15%
Employee Growth %
$213.1M
Valuation
N/A
Accelerator
Ovid Therapeutics News
Ovid Therapeutics reported earnings per share of $2.53 in the same quarter last year, which would indicate a negative year over year growth rate...
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ... in the epilepsy therapeutic market, which is available to Needham...
Ovid Therapeutics, Inc is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare...
In an interview at the BIO conference in Philadelphia Wednesday, Levin said rare diseases will be a particular area of interest for him at the organization. Ovid is also focused on development of rare neurological diseases, and its most advanced drug candidate is OV101, for Angelman syndrome – a ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.4M | 46 | -39% | N/A |
#2 | $8.9M | 46 | -30% | N/A |
#3 | $35M | 46 | 35% | N/A |
#4 | $6.7M | 46 | -10% | N/A |
#5 | $7.5M | 46 | -4% | N/A |